X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr Reddy’s: A volatile story - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dr Reddy’s: A volatile story

Dec 9, 2004

Dr Reddy’s has been one of the most revered domestic pharmaceutical companies. The reverence for the company is due to its vision to be a research driven company and the company has been valued more than any other in the Indian pharma sector. Dr Reddy’s has been one of the first few companies in the country to enter in NCE (new chemical entity) research and spending a large proportion of its revenue on the same. Despite these positives, the stock of the company has been ‘hammered’ in recent times. Let us delve into the reasons for this volatility.

The revenue front… Dr Reddy’s has been following a business strategy, which has subjected its revenues and profits to a high degree of volatility. Here, let us first understand the sources of revenue for the company. There are three major sources of revenue for Dr. Reddy’s –

  1. Formulations,

  2. APIs (active pharmaceutical ingredients), and

  3. Generics.

Formulations and APIs are two stable sources of revenues for the company. However, the generics business has seen a high degree of volatility in terms of contribution to revenues (see graph below), much of which can be attributed to strategy followed by the company for this business segment. Dr Reddy’s believes in applications under Para IV, which means that if the company is successful in its application, it can witness a huge upside on both revenues and profits front as it happened in case of Fluoxetine. However, if the company loses the case, money spent on costly legal battle will affect its profitability, as was evident in the case of Amlodipine Maleate. Also, in case of Para IV successes, revenues tend to decline after the exclusivity period (six months) comes to an end as more competitors enter the market.

The profitability front…
The change in business mix towards increased contribution from APIs has severely impacted the profitability of Dr. Reddy’s as generics and formulations are more profitable as compared to the API business. Another factor that has affected profitability of Dr Reddy’s is higher SG&A (sales, general and administrative) expenses and R&D (research and development) expenses. For instance, the SG&A expenses have increased by 32% CAGR in the past four years, much higher compared to the 22% CAGR of revenues. Similar is the case with R&D expenditure which has risen with 40% CAGR during this period. The major increase in these expenses has come up in the last 5-6 quarters and we believe that the investment in SG&A expenses will have long-term implications, in terms of revving up the company’s distribution and marketing network in the US and other global generic markets. On the R&D front, the company has two major areas of work i.e. NCE and ANDA (abbreviated new drug application). While, off late, Dr. Reddy’s has increased its spending towards R&D on the ANDA front, the NCE research will take its time to reap any benefit.

What to expect? We believe that the expenditure on SG&A and R&D fronts are in line with the long-term vision of the company. These expenses are actually investments for the future and the benefits are likely to accrue in the long run. We would like to quote Ranbaxy on this front, which invested heavily in building sales and distribution network in the US markets in the past four years, the benefits of which have started accruing now. We foresee the same thing happening with Dr Reddy’s going forward.

At Rs 834, the stock is trading 32.2 times our expected FY05 earnings. While the last three quarters for the company have been terrible on both revenue growth as well as profitability fronts, we believe that the worse may be over for the company. The investments in sales and distribution and R&D (basically on the ANDA front) are likely to start paying of dividends going forward. While we may see volatility in the stock price in the short term as decisions on some Para IV challenges are likely to come, we are positive on the company from the long-term perspective.


Equitymaster requests your view! Post a comment on "Dr Reddy’s: A volatile story". Click here!

  

More Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

The Best Trading Strategy in the World(Profit Hunter)

Apr 15, 2019

It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...

A Letter to You from India's No. 1 Trader(The 5 Minute Wrapup)

Apr 15, 2019

It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...

Election Series: Why 'Liquor' is so Important to the Elections(The 5 Minute Wrapup)

Apr 19, 2019

When elections come around, liquor flows like water and everyone gets drunk with power...what does this mean for liquor stocks? Read one to find out from our very own election trading analyst, Vijay Bhambwani.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Apr 26, 2019 03:05 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - ALEMBIC PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS